A298060 Stock Overview
Operates in the stem cell therapy, CMO, contract research and consulting, and cosmetic businesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
SCM Lifescience Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,863.00 |
| 52 Week High | ₩4,600.00 |
| 52 Week Low | ₩1,609.00 |
| Beta | 1.17 |
| 11 Month Change | -3.92% |
| 3 Month Change | -17.75% |
| 1 Year Change | -35.31% |
| 33 Year Change | -84.64% |
| 5 Year Change | n/a |
| Change since IPO | -93.81% |
Recent News & Updates
SCM Lifescience (KOSDAQ:298060) Has Debt But No Earnings; Should You Worry?
Nov 01
Is SCM Lifescience (KOSDAQ:298060) Using Too Much Debt?
Jul 05Is SCM Lifescience (KOSDAQ:298060) Using Debt In A Risky Way?
Feb 29Shareholder Returns
| A298060 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 8.9% | -4.2% | 1.9% |
| 1Y | -35.3% | 19.5% | -2.6% |
Return vs Industry: A298060 underperformed the KR Biotechs industry which returned 19.5% over the past year.
Return vs Market: A298060 underperformed the KR Market which returned -2.6% over the past year.
Price Volatility
| A298060 volatility | |
|---|---|
| A298060 Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A298060's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A298060's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Byeong-gwan Son | www.scmlifescience.co.kr |
SCM Lifescience Co., Ltd. operates in the stem cell therapy, CMO, contract research and consulting, and cosmetic businesses. The company develops allogeneic stem cell therapeutics using its stem cell isolation technology and conducting clinical trials for immunological conditions and tissue regeneration; provides CMO services for manufacturing control and quality assurance tests; and offers adult stem cell research services. It also provides skin cell science services.
SCM Lifescience Co., Ltd. Fundamentals Summary
| A298060 fundamental statistics | |
|---|---|
| Market cap | ₩38.15b |
| Earnings (TTM) | -₩15.65b |
| Revenue (TTM) | ₩889.44m |
42.9x
P/S Ratio-2.4x
P/E RatioIs A298060 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A298060 income statement (TTM) | |
|---|---|
| Revenue | ₩889.44m |
| Cost of Revenue | ₩477.40m |
| Gross Profit | ₩412.04m |
| Other Expenses | ₩16.06b |
| Earnings | -₩15.65b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -764.50 |
| Gross Margin | 46.33% |
| Net Profit Margin | -1,759.22% |
| Debt/Equity Ratio | 30.8% |
How did A298060 perform over the long term?
See historical performance and comparison